<bill session="116" type="h" number="3105" updated="2019-10-23T15:09:01Z">
  <state datetime="2019-06-05">REFERRED</state>
  <status>
    <introduced datetime="2019-06-05"/>
  </status>
  <introduced datetime="2019-06-05"/>
  <titles>
    <title type="official" as="introduced">To establish an annual fee applicable to opioid manufacturers.</title>
    <title type="short" as="introduced">Opioid Treatment Surge Act</title>
    <title type="short" as="introduced">Opioid Treatment Surge Act</title>
    <title type="display">Opioid Treatment Surge Act</title>
  </titles>
  <sponsor bioguide_id="B001278"/>
  <cosponsors/>
  <actions>
    <action datetime="2019-06-05">
      <text>Introduced in House</text>
    </action>
    <action datetime="2019-06-05" state="REFERRED">
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </action>
  </actions>
  <committees>
    <committee subcommittee="" code="HSIF" name="House Energy and Commerce" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill type="s" session="116" relation="identical" number="1662"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Drug, alcohol, tobacco use"/>
    <term name="Health care coverage and access"/>
    <term name="Prescription drugs"/>
    <term name="User charges and fees"/>
  </subjects>
  <amendments/>
  <summary date="2019-06-05T04:00:00Z" status="Introduced in House">Opioid Treatment Surge ActThis bill requires the Department of Health and Human Services to assess market-share-based fees, for the next 10 years, on drug manufacturers that have produced opioid drugs since 1999. Opioid drugs manufactured to treat opioid addiction, cancer patients, or hospice patients are, however, exempt from this assessment. All assessed fees must be used for the substance abuse prevention and treatment block grant program.</summary>
  <committee-reports/>
</bill>
